James B. Bussel

37.5k total citations · 6 hit papers
514 papers, 21.1k citations indexed

About

James B. Bussel is a scholar working on Hematology, Genetics and Immunology. According to data from OpenAlex, James B. Bussel has authored 514 papers receiving a total of 21.1k indexed citations (citations by other indexed papers that have themselves been cited), including 460 papers in Hematology, 127 papers in Genetics and 124 papers in Immunology. Recurrent topics in James B. Bussel's work include Platelet Disorders and Treatments (430 papers), Blood groups and transfusion (270 papers) and Autoimmune Bullous Skin Diseases (99 papers). James B. Bussel is often cited by papers focused on Platelet Disorders and Treatments (430 papers), Blood groups and transfusion (270 papers) and Autoimmune Bullous Skin Diseases (99 papers). James B. Bussel collaborates with scholars based in United States, United Kingdom and Canada. James B. Bussel's co-authors include Douglas B. Cines, Nichola Cooper, Bertrand Godeau, Drew Provan, Bethan Psaila, Marc Michel, Mansoor N. Saleh, Roberto Stasi, Robert McMillan and Gregory Cheng and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

James B. Bussel

490 papers receiving 20.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group

2008 1.9k citations Francesco Rodeghiero, Roberto Stasi et al. Blood profile →
The ITP syndrome: pathogenic and clinical diversity

2009 566 citations James B. Bussel et al. Blood profile →
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

2007 565 citations James B. Bussel, Mansoor N. Saleh et al. profile →
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination

2021 270 citations Eun‐Ju Lee, Marc Michel et al. American Journal of Hematology profile →
Thrombopoietin receptor agonists: ten years later

2019 248 citations Nichola Cooper, Francesco Rodeghiero et al. profile →
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

2018 237 citations James B. Bussel, Nichola Cooper et al. American Journal of Hematology profile →

Peers

Countries citing papers authored by James B. Bussel

Since Specialization

Citations

This map shows the geographic impact of James B. Bussel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Bussel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Bussel more than expected).

Fields of papers citing papers by James B. Bussel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Bussel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Bussel. The network helps show where James B. Bussel may publish in the future.

Co-authorship network of co-authors of James B. Bussel

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Bussel. A scholar is included among the top collaborators of James B. Bussel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Bussel. James B. Bussel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rising to the challenge: an international Delphi consensus study on fetal and neonatal alloimmune thrombocytopenia 2025 ·The Lancet Haematology ·(unknown), M. Elske van den Akker‐van Marle, (unknown), Heidi Tiller, James B. Bussel, Maria Therese Ahlén, Brian R. Curtis, Enrico Lopriore, E. J. T. Verweij, Masja de Haas	2
2	Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia (FREESIA-3) 2024 ·Blood ·James B. Bussel, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
3	Does anti‐HPA‐1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia? 2024 ·Pediatric Blood & Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Amihai Rottenstreich, Rick Kapur, Huiying Zhi, Debra K. Newman, (unknown), James B. Bussel	2
4	Improving the chances of response to splenectomy in immune thrombocytopenia 2023 ·British Journal of Haematology ·Sylvain Audia, James B. Bussel	0
5	Identifying Pregnancies at Higher Risk for HPA-1a Alloimmunization and Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT): An International, Prospective, Natural History Study 2023 ·Blood ·(unknown), (unknown), (unknown), Róisín Armstrong, Dawn Black, (unknown), (unknown), (unknown), Russell S. Miller, Surabhi Nanda, Michael J. Paidas, Kiran C. Patki, Vasilis Sitras, Daniel Skupski, (unknown), John M. Thorp, Heidi Tiller, E. J. T. Verweij, James B. Bussel	2
6	Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV) 2023 ·Blood ·Catherine M. Broome, Vickie McDonald, Yoshitaka Miyakawa, Monica Carpenedo, David J. Kuter, Hanny Al‐Samkari, James B. Bussel, Anna Hultberg, Filip Matthijssens, (unknown), Kristof De Beuf, Francesco Rodeghiero, Marc Michel, Adrian C. Newland	1
7	Maintenence rituximab following induction in autoimmune cytopenias 2023 ·British Journal of Haematology ·P Manoj, Eun‐Ju Lee, James B. Bussel	1
8	Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence 2023 ·Annals of Hematology ·Adam Cuker, (unknown), (unknown), (unknown), (unknown), James B. Bussel	2
9	Quality of life is an important indication for second‐line treatment in children with immune thrombocytopenia 2021 ·Pediatric Blood & Cancer ·Kristin A. Shimano, Cindy Neunert, James B. Bussel, Robert J. Klaassen, Rukhmi Bhat, Yves Pastore, Michele P. Lambert, Carolyn M. Bennett, Jenny M. Despotovic, Peter Forbes, Rachael F. Grace	8
10	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study 2017 ·Blood ·Raymond Wong, Mansoor N. Saleh, Abderrahim Khélif, Abdulgabar Salama, Maria Socorro O Portella, Paul Burgess, James B. Bussel	215
11	Improvements in Patient Health-Related Quality of Life (HRQoL) with Clinical Efficacy in Patients Treated with Eltrombopag: Final Results from the Long-Term, Open-Label Extend Study 2016 ·Blood ·Mansoor N. Saleh, James B. Bussel, Abderrahim Khélif, Paul Burgess, (unknown), Anuja Roy, Victoria Barghout, Mei Sheng Duh, Kelly M. Grotzinger, Abdulgabar Salama	3
12	Platelet count control in immune thrombocytopenic purpura patient: Optimum romiplostim dose profile 2016 ·Journal of Process Control ·(unknown), James B. Bussel, (unknown), Stanley I. Sandler, Babatunde A. Ogunnaike	4
13	Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia 2015 ·Blood ·Anja J. Gerrits, Emily Leven, Andrew L. Frelinger, (unknown), Michelle A. Berny‐Lang, W. Beau Mitchell, Shoshana Revel‐Vilk, Hannah Tamary, Sabrina L. Carmichael, Marc R. Barnard, Alan D. Michelson, James B. Bussel	58
14	Review of fetal and neonatal immune cytopenias. 2015 ·PubMed ·Sharon R. Lewin, James B. Bussel	12
15	Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy 2013 ·British Journal of Haematology ·David J. Kuter, James B. Bussel, Adrian C. Newland, Ross Baker, Roger M. Lyons, Jeffrey S. Wasser, Jean‐François Viallard, Gail Macik, Mathias Rummel, Kun Nie, Susie Jun	203
16	Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia 2012 ·Blood ·Vivek Patel, Matthieu Mahévas, Soo Yong Lee, Roberto Stasi, Susanna Cunningham–Rundles, Bertrand Godeau, Julie Kanter, Ellis J. Neufeld, Tillmann Taube, Ugo Ramenghi, Shalini Shenoy, Mary J. Ward, Nino Mihatov, (unknown), Philippe Bierling, Martin Lesser, Nichola Cooper, James B. Bussel	243
17	A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia 2011 ·Blood ·James B. Bussel, George R. Buchanan, Diane J. Nugent, David J. Gnarra, Lisa Bomgaars, Victor S. Blanchette, (unknown), Kun Nie, (unknown)	157
18	Fetal and Neonatal Alloimmune Thrombocytopenia 2011 ·Obstetrics and Gynecology ·Luis D. Pacheco, Richard L. Berkowitz, Kenneth J. Moise, James B. Bussel, Janice G. McFarland, George R. Saade	61
19	Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents 2010 ·Blood ·Weili Bao, James B. Bussel, Susanne Heck, Wu He, Marissa Karpoff, Nayla Boulad, Karina Yazdanbakhsh	245
20	Is it necessary to test patients with immune thrombocytopenic purpura (ITP) for seropositivity to HTLV-1? 1999 ·American Journal of Hematology ·Elizabeth Calleja, (unknown), James B. Bussel	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact